Abbvie Inc (ABBV)

$208.42 -1.84 (-0.88%)
Market Cap 365.07B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.79
Forward PE 14.72
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 5,814,408
Avg Vol 7,141,244
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 46%
Beta 0.38
Analysts Strong Sell
Price Target $249.71

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Guntz
Guntz Apr. 15 at 5:12 PM
$ABBV Double bottom?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 15 at 4:59 PM
$SLS How long ago was this Statement ? - its Now Mid April - nicely into Q2. - Ps if you don't know for sure, 100% absolutely for Sure Gps is Golden, Getting FDA Approval, and SLS is worth Exponentially More than the current Manipulated Share Price --- you are in a dwindling minority. Gps has proven effective in 9 Prior Trials, Including 2 Phase 2 AML Remission Maintenance Trials, with OS correlated to Immune response. - and while we are seeing miraculous all pooled survival, with at least 47 patients remaining alive at least 25 months (Historical MOS is 6-8) - the BAT, Best Available Treatment for Control Arm Patients Recently FAILED, 3 Large Phase 3 Trials, $ABBV $BMY - including Failing the VIALE-M and VIALE-T Remission Maintenance trials. Its not complicated. Buy and HOLDL as Many As you can.
0 · Reply
LongJohnOption
LongJohnOption Apr. 15 at 4:30 PM
$ABBV Ive owned this for a long time, and always will. However it infuriates me
1 · Reply
trenddetector
trenddetector Apr. 15 at 2:37 PM
$GILD $BMY $ABBV $AMGN $NVS I built the tool I wish I had 16 years ago. If you or a loved one is facing a diagnosis, don't navigate it in the dark. www.YourCancerPath.com is a free, anonymous way to map out diagnostic steps and find live clinical trials without the medical jargon. Pass it on—it could be a lifeline for someone today.
0 · Reply
Guntz
Guntz Apr. 15 at 1:58 PM
$ABBV Let's get another $74 million buy hehe
0 · Reply
himsssss
himsssss Apr. 15 at 4:04 AM
$VKTX What happened? I thought $ABBV was supposed to buy this out like months ago. Didn't they like add each other facebook according to bioloser.
1 · Reply
shopno
shopno Apr. 15 at 12:25 AM
$ABBV $AZN $PFE $RVMD All these data based on Q4 2025. $MRK had 18B cash and 40B debts, so likely they were stringent on paying top premiums. In either case, I am absolutely fine if RVMD just does a partnership. Market valuation can go 50% over what anyone could pay (35-40B).
0 · Reply
shopno
shopno Apr. 15 at 12:20 AM
$RVMD $ABBV can’t afford 40B BO with <$6B cash on had and $63B debts! $AZN also got too little cash (6B), but their debts not as bad (25B). Like ABBV $PFE cannot afford RVMD— only 15B cash and massive 57B debts — $43B seagen acquisition in 2023 still not paying them off, as revenue just in $3B+ a year. PFE could afford acquiring SGEN, as they had 44B cash and 31B debt (net 13B cash) before the acquisition: https://www.macrotrends.net/stocks/charts/PFE/pfizer/long-term-debt BMS is bit better— 11B cash and 43B debts (net debt -32B). Roche is stronger financially with net debt -14B. LLY has large debts, but they have strong income growth. Not sure if they would ever acquire a company 5x of their highest ever acquisition!
0 · Reply
Creisi
Creisi Apr. 14 at 6:01 PM
$ABBV $MLTX Doxtator from day 1, saw this as an expert. Right now this is simply the "Blue Light Sale" at K-mart. $MLTX shares are disgustingly underpriced at $20 because the vast majority of the market have no idea what's coming... This is the perfect storm of opportunity; and if anything, I am underestimating what's going to happen as trial results start being released in May... This is the Best Buy in all of clinical biopharma; RIGHT NOW! Even co-payers will love it. There's a lot of 'Stalking Horses' all over MLTX and as soon as the data starts rolling in; the bids are going to start sprinting upwards... ABBVIE's life depends on owning SLK. Merck, Lilly, Sanofi, would pay extra just to crush them and MLTX executives know it. Jorge is building the 'Perfect M&A target asset STORM' !!
3 · Reply
Guntz
Guntz Apr. 14 at 5:33 PM
$ABBV Damn someone just bought $74 million in shares
1 · Reply
Latest News on ABBV
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Apr 15, 2026, 8:16 AM EDT - 9 hours ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

MDT

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 1 day ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 2 days ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 3 days ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 7 days ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 7 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 8 days ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 8 days ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 12 days ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 12 days ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 12 days ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 13 days ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 13 days ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 15 days ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 15 days ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 19 days ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 22 days ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 26 days ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 27 days ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 27 days ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 4 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 4 weeks ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 4 weeks ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 6 weeks ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 6 weeks ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 7 weeks ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 7 weeks ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 7 weeks ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 20, 2026, 2:00 AM EST - 7 weeks ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 7 weeks ago

AbbVie Declares Quarterly Dividend

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 2 months ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 2 months ago

Abbvie sues US health agency over Botox

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Feb 4, 2026, 12:38 PM EST - 2 months ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 2 months ago

AbbVie Revenue Rises on Immunology Growth

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 8:18 AM EST - 2 months ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:51 AM EST - 2 months ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 4, 2026, 7:48 AM EST - 2 months ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:50 AM EST - 2 months ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Feb 3, 2026, 8:00 AM EST - 2 months ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 29, 2026, 8:00 AM EST - 2 months ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 28, 2026, 8:00 AM EST - 2 months ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 2 months ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 27, 2026, 9:34 AM EST - 2 months ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:43 PM EST - 3 months ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

Jan 16, 2026, 1:35 PM EST - 3 months ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

AbbVie plans to build out its presence in obesity market

Jan 14, 2026, 2:01 PM EST - 3 months ago

AbbVie plans to build out its presence in obesity market

AbbVie reaches 3-year deal with White House to lower drug prices

Jan 13, 2026, 7:22 AM EST - 3 months ago

AbbVie reaches 3-year deal with White House to lower drug prices

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

Jan 13, 2026, 5:24 AM EST - 3 months ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Jan 12, 2026, 7:03 PM EST - 3 months ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Guntz
Guntz Apr. 15 at 5:12 PM
$ABBV Double bottom?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 15 at 4:59 PM
$SLS How long ago was this Statement ? - its Now Mid April - nicely into Q2. - Ps if you don't know for sure, 100% absolutely for Sure Gps is Golden, Getting FDA Approval, and SLS is worth Exponentially More than the current Manipulated Share Price --- you are in a dwindling minority. Gps has proven effective in 9 Prior Trials, Including 2 Phase 2 AML Remission Maintenance Trials, with OS correlated to Immune response. - and while we are seeing miraculous all pooled survival, with at least 47 patients remaining alive at least 25 months (Historical MOS is 6-8) - the BAT, Best Available Treatment for Control Arm Patients Recently FAILED, 3 Large Phase 3 Trials, $ABBV $BMY - including Failing the VIALE-M and VIALE-T Remission Maintenance trials. Its not complicated. Buy and HOLDL as Many As you can.
0 · Reply
LongJohnOption
LongJohnOption Apr. 15 at 4:30 PM
$ABBV Ive owned this for a long time, and always will. However it infuriates me
1 · Reply
trenddetector
trenddetector Apr. 15 at 2:37 PM
$GILD $BMY $ABBV $AMGN $NVS I built the tool I wish I had 16 years ago. If you or a loved one is facing a diagnosis, don't navigate it in the dark. www.YourCancerPath.com is a free, anonymous way to map out diagnostic steps and find live clinical trials without the medical jargon. Pass it on—it could be a lifeline for someone today.
0 · Reply
Guntz
Guntz Apr. 15 at 1:58 PM
$ABBV Let's get another $74 million buy hehe
0 · Reply
himsssss
himsssss Apr. 15 at 4:04 AM
$VKTX What happened? I thought $ABBV was supposed to buy this out like months ago. Didn't they like add each other facebook according to bioloser.
1 · Reply
shopno
shopno Apr. 15 at 12:25 AM
$ABBV $AZN $PFE $RVMD All these data based on Q4 2025. $MRK had 18B cash and 40B debts, so likely they were stringent on paying top premiums. In either case, I am absolutely fine if RVMD just does a partnership. Market valuation can go 50% over what anyone could pay (35-40B).
0 · Reply
shopno
shopno Apr. 15 at 12:20 AM
$RVMD $ABBV can’t afford 40B BO with <$6B cash on had and $63B debts! $AZN also got too little cash (6B), but their debts not as bad (25B). Like ABBV $PFE cannot afford RVMD— only 15B cash and massive 57B debts — $43B seagen acquisition in 2023 still not paying them off, as revenue just in $3B+ a year. PFE could afford acquiring SGEN, as they had 44B cash and 31B debt (net 13B cash) before the acquisition: https://www.macrotrends.net/stocks/charts/PFE/pfizer/long-term-debt BMS is bit better— 11B cash and 43B debts (net debt -32B). Roche is stronger financially with net debt -14B. LLY has large debts, but they have strong income growth. Not sure if they would ever acquire a company 5x of their highest ever acquisition!
0 · Reply
Creisi
Creisi Apr. 14 at 6:01 PM
$ABBV $MLTX Doxtator from day 1, saw this as an expert. Right now this is simply the "Blue Light Sale" at K-mart. $MLTX shares are disgustingly underpriced at $20 because the vast majority of the market have no idea what's coming... This is the perfect storm of opportunity; and if anything, I am underestimating what's going to happen as trial results start being released in May... This is the Best Buy in all of clinical biopharma; RIGHT NOW! Even co-payers will love it. There's a lot of 'Stalking Horses' all over MLTX and as soon as the data starts rolling in; the bids are going to start sprinting upwards... ABBVIE's life depends on owning SLK. Merck, Lilly, Sanofi, would pay extra just to crush them and MLTX executives know it. Jorge is building the 'Perfect M&A target asset STORM' !!
3 · Reply
Guntz
Guntz Apr. 14 at 5:33 PM
$ABBV Damn someone just bought $74 million in shares
1 · Reply
maikl_211
maikl_211 Apr. 14 at 5:10 PM
$ABBV $MU $GE $PG $CVX
0 · Reply
Guntz
Guntz Apr. 14 at 5:02 PM
$ABBV All day to go up 1 percent and now about to lose it all in 30 mins 🙄
0 · Reply
dewmoore
dewmoore Apr. 14 at 3:44 PM
$SLS I'm so grateful to pick up MORE shares under $5.00 this is simply GOD! Our NEW floor is $172.00 we are the new "KEYTRUDA KILLERS" !!!!!!! Dear God -10k shares of SLS at $172 is worth what? Dear Son: You would make around $1.72 MILLION!!!! before SATAN (uncle sam) takes his cut LOL The Tax Hit Federal Capital Gains (20%): $344,000 Net Investment Income Tax (3.8%): $65,360 Florida State Tax (0%): $0 Total Estimated Tax: $409,360 Your Net Take-Home $1,310,640 THANK YOU JESUS !!!! Hey $MRK Hey $LLY Hey $PFE Hey $ABBV
0 · Reply
Guntz
Guntz Apr. 14 at 3:26 PM
$ABBV What are we doing? Let's get a move on it lol
0 · Reply
SunnySeed
SunnySeed Apr. 14 at 1:55 PM
$SLS Can’t wait for the 1:1 $ABBV buyout gonna be an amazing life for everyone!
0 · Reply
Guntz
Guntz Apr. 14 at 1:46 PM
$ABBV Allegeric to green
0 · Reply
wwmeinc
wwmeinc Apr. 14 at 1:23 PM
$VKTX $LLY $NVO $JNJ $ABBV ......KLRA's S-1 released...looking for a $14-$16 IPO price but not set in stone yet...14 M shares maybe...or more...looks like they are planning on this upcoming Friday as a trading start...money coming to our sector.....helps in keeping our name on top to my eyes....but that is just my opinion...glta https://www.iposcoop.com/the-ipo-buzz-obesity-focused-kailera-therapeutics-sets-500-million-ipo/
1 · Reply
Quantumup
Quantumup Apr. 14 at 10:43 AM
H.C. Wainwright y'day⬆️ $ORKA's PT to $70, plus⬆️ORKA-001/002's probability of approval to 50/40% and reiterated at Buy after it said the ORKA-001 EVERLAST-A data readout "appears imminent." $JNJ PTGX $ABBV $ALMS VNDA MLTX BMY UCBJY Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2044002725562634472?s=20
0 · Reply
Guntz
Guntz Apr. 13 at 9:14 PM
$ABBV Closed a little higher and it would have been a nice hammer on the daily.
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 13 at 9:01 PM
$ABBV Share Price: $206.47 Contract Selected: May 08, 2026 $210 Calls Buy Zone: $3.53 – $4.36 Target Zone: $6.26 – $7.65 Potential Upside: 68% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Guntz
Guntz Apr. 13 at 7:37 PM
$ABBV Let's pull a $PFE 😁
0 · Reply
profit_guru
profit_guru Apr. 13 at 5:33 PM
$ABBV - $JNJ releases earnings tomorrow if they have strong quarter it will rally whole biotech
0 · Reply